Anupam Rasayan India Ltd - 543275 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations - Draft Letter Of Offer
Anupam Rasayan launched a mandatory open offer to acquire 26% of Bliss GVS Pharma's equity at ₹299 per share, following a prior acquisition of 43.30% stake. The offer is valued at ₹829.03 crore.
Jun 09 2026 19:49:32
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Anupam Rasayan has scheduled an investor meet and plant visit for June 09, 2026, with Prabhudas Liladhar at its Jhagadia GIDC Plant in Gujarat. Discussions will be based on information already in the public domain, with no unpublished price sensitive information intended to be shared. The Q4 FY2024-25 Investor Presentation will be used.
Jun 04 2026 18:22:40
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Credit Rating
Anupam Rasayan's credit ratings for issuer, bank facilities, and NCDs were maintained on 'Rating Watch with Negative Implications' by Ind-Ra. This is due to uncertainty regarding the sustainable capital structure after the acquisition of a controlling stake in Bliss GVS Pharma Limited, which involves significant debt funding.
Jun 03 2026 21:05:09
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Credit Rating
Crisil Ratings placed Anupam Rasayan's bank facilities and NCDs on 'Rating Watch with Developing Implications'. This action follows the company's announced acquisition of Bliss GVS Pharma and uncertainty surrounding its funding structure.
Jun 03 2026 13:18:03
Anupam Rasayan India Ltd - 543275 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Anupam Rasayan promoter Anand Sureshbhai Desai pledged 31.5 lakh equity shares. This represents 2.77% of the company's total share capital and serves as security for Non-Convertible Debentures (NCDs) issued by the company.
Jun 02 2026 10:26:57
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Anupam Rasayan has made the audio recording of its Q4 FY26 earnings call available online. Investors can access the discussion on the company's audited financial results from its website.
May 25 2026 21:06:03
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Anupam Rasayan reported strong FY26 financial results with revenue up 65% YoY to Rs.2,383.6 crore and net profit up 39% to Rs.222.2 crore. Q4 revenue increased by 26% YoY, though net profit declined by 11% in the quarter.
May 23 2026 20:26:57
Anupam Rasayan India Ltd - 543275 - Corporate Action-Board approves Dividend
Anupam Rasayan board recommended a final dividend of ₹1.50 per equity share for FY26. This dividend is 15% of the ₹10 face value and awaits shareholder approval at the upcoming 23rd AGM.
May 23 2026 19:58:42
Anupam Rasayan India Ltd - 543275 - Announcement Under Regulation 30 Of SEBI LODR
Anupam Rasayan India Ltd. board approved the acquisition of up to 74.20% equity shares and control of Bliss GVS Pharma Ltd., a pharmaceutical company. The total acquisition value is approximately Rs. 2,198 crore, enhancing its presence in the pharmaceutical value chain.
May 23 2026 19:51:40
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Acquisition
Anupam Rasayan has approved the acquisition of up to 74.20% stake in Bliss GVS Pharma Ltd. for an aggregate consideration of approximately Rs. 2198.54 crore. This strategic move aims to strengthen its pharmaceutical value chain and enhance global presence.
May 23 2026 19:37:46
Read More